Control and Intervention Programme on Alzheimer's Disease Risk Factors (ALFAlife)

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

Status

Completed

Conditions

Alzheimer's Disease

Treatments

Other: Lifestyle recommendations

Study type

Interventional

Funder types

Other

Identifiers

NCT02772523

ALFAlife/BBRC2015

Details and patient eligibility

About

Recent epidemiologic studies are identifying a number of modifiable risk and protective factors that may influence in the incidence of Alzheimer's disease (AD). Therefore, the combination of an early detection of individuals at risk together with interventional studies targeted to the control of modifiable risk factors makes primary prevention programmes to become a new and real therapeutic strategy.

In this scenario, the investigators have designed the ALFAlife study, a programme of control and intervention on the modifiable AD risk factors. Throughout this study, participants will be given a number of healthy lifestyle guidelines that are personalised depending on their specific risk profile. These guidelines refer to smoking and dietary habits and physical, cognitive and social activity. The investigators hypothesis is that the follow-up of these guidelines will favor a change of participants' lifestyle habits towards healthier ones. In addition, the investigators hypothesise that changes in these lifestyle habits will have an effect on objective physiological measures (such as blood pressure and cholesterol levels).

Enrollment

409 patients

Sex

All

Ages

45 to 78 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Participants in the ALFA study (NCT01835717)
Computer literacy
Accept study's tests and procedures
Signature of informed consent

Exclusion criteria

Cognitive impairment assessed by clinical criteria that, according to the investigator's evaluation could interfere with the study's follow-up.
Anxiety or depression assessed by clinical criteria that, according to the investigator's evaluation could interfere with the study's follow-up.
Visual and/or hearing impairment severe enough to impede tests realization.
Major psychiatric or neurological disorder or other diseases that according to the investigator's evaluation could interfere with the study's follow-up.
Antecedents of infarction, ischemic heart disease, stroke, peripheral vascular disease, stent or aneurysm clip